Letermovir for Cytomegalovirus Prophylaxis in Heart Transplant Recipients
Year: 2025
Type: article
Abstract: Purpose: Letermovir has been shown to reduce the risk of CMV infection when used as prophylaxis in allogeneic hematopoietic cell transplantation. However, data on its efficacy in heart transplantation (HT) are limited. The aim of this study was to evaluate the safety, efficacy, and clinical use of letermovir for cytomegalovirus prophylaxis in HT recipients.
Authors: T. Sato, S. Takenaka, M. Ikura, T. Iwanaga, H. Mochizuki, R. Shiomura, T. Watanabe, T. Nagai, S. Fukushima, S. Wakasa, T. Anzai, Y. Tsukamoto
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,300
OpenAlex ID: W4412865652